Benazepril — Discount Pricing

Other medications in Heart & Cardiovascular

• Bisoprolol
• Bosentan
• Bumetanide
• Candesartan
• Cangrelor
• Captopril
• Carvedilol
• Chlorthalidone

What Benazepril is approved for (FDA label)

Benazepril Hydrochloride Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: August 19, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Benazepril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benazepril Hydrochloride Tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ]. WARNING – FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Benazepril Hydrochloride Tablets as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Benazepril (FDA label)

Tablets: 5 mg, 10 mg, 20 mg, and 40 mg • Each 5 mg tablet is light yellow, capsule-shaped, film-coated, debossed with “ANI” on one side and “524” on the other. • Each 10 mg tablet is dark yellow, capsule-shaped, film-coated, debossed with “ANI” on one side and “525” on the other. • Each 20 mg tablet is light pink, capsule-shaped, film-coated, debossed with “ANI” on one side and “526” on the other. • Each 40 mg tablet is dark pink capsule-shaped, film-coated, debossed with “ANI” on one side and “527” on the other. • Tablets: 5 mg, 10 mg, 20 mg, 40 mg

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Benazepril (FDA label)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Benazepril hydrochloride has been evaluated for safety in over 6000 patients with hypertension; over 700 of these patients were treated for at least one year. The overall incidence of reported adverse events was similar in benazepril hydrochloride and placebo patients. The reported side effects were generally mild and transient, and there was no relation between side effects and age, duration of therapy, or total dosage within the range of 2 to 80 mg. Discontinuation of therapy because of a side effect was required in approximately 5% of U.S. patients treated with benazepril hydrochloride and in 3% of patients treated with placebo. The most common reasons for discontinuation were headache (0.6%) and cough (0.5%). Adverse reactions seen in at least 1% greater frequency in patients treated with benazepril hydrochloride than placebo were headache (6% vs. 4%), dizziness (4% vs. 2%), somnolence (2% vs. 0%) and postural dizziness (2% vs. 0%). Adverse reactions reported in controlled clinical trials (less than 1% more on benazepril than on placebo), and rarer events seen in post-marketing experience, include the following (in some, a causal relationship to drug use is uncertain): Dermatologic: Stevens-Johnson syndrome, pemphigus, apparent hypersensitivity reactions (manifested by dermatitis, pruritus, or rash), photosensitivity, and flushing. Gastrointestinal: Nausea, pancreatitis, constipation, gastritis, vomiting, and melena. Hematologic: Thrombocytopenia and hemolytic anemia. Neurologic/Psychiatric: Anxiety, decreased libido, hypertonia, insomnia, nervousness, and paresthesia Other: Fatigue, asthma, bronchitis, dyspnea, sinusitis, urinary tract infection, frequent urination, infection, arthritis, impotence, alopecia, arthralgia, myalgia, asthenia, sweating. Laboratory Abnormalities: Elevations of uric acid, blood glucose, serum bilirubin, and liver enzymes [see Warnings and Precautions (5) ] have been reported, as have incidents of hyponatremia, electrocardiographic changes, eosinophilia, and proteinuria. The most common adverse reactions leading to discontinuation were headache (0.6%) and cough (0.5%) ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Benazepril (FDA label)

Benazepril Hydrochloride Tablets are contraindicated in patients: • who are hypersensitive to benazepril or to any other ACE inhibitor • with a history of angioedema with or without previous ACE inhibitor treatment Benazepril Hydrochloride Tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Benazepril Hydrochloride Tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2) ] . Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including; Benazepril Hydrochloride Tablets in patients with diabetes [see Drug Interactions (7.4) ] . • Angioedema or history of hereditary or idiopathic angioedema ( 4 ) • Hypersensitivity ( 4 ) • Coadministration with aliskiren in patients with diabetes ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Benazepril (FDA label)

• Angioedema: Discontinue benazepril hydrochloride and treat appropriately. ( 5.2 ) • Monitor renal function periodically. ( 5.3 ) • Monitor blood pressure after initiation. ( 5.4 ) • Hyperkalemia: Monitor serum potassium periodically. ( 5.5 ) • Hepatic toxicity: Monitor for jaundice or signs of liver failure. ( 5.6 ) 5.1. Fetal Toxicity Benazepril hydrochloride can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Benazepril (FDA label)

• Diuretics: Excessive drop in blood pressure ( 7.1 ) • Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) • NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) • Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia ( 7.4 ) • Lithium: Symptoms of lithium toxicity ( 7.6 ) • Neprilysin Inhibitor: Increased risk of angioedema ( 7.7 ) • Gold: Nitritoid reactions ( 7.8 ) 7.1. Diuretics Hypotension Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with benazepril hydrochloride.

Source: FDA prescribing information (DailyMed). Set ID: ff732cfa-9ded-4226-b464-19c90a6865ae. SPL document ID: c7a71b00-b447-4a1a-b8dc-6a04467c9268. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.